WO2018070707A1 - Composition pour la prévention ou le traitement de maladie musculaire, contenant comme principe actif decanal ou un sel pharmaceutiquement acceptable de celui-ci - Google Patents

Composition pour la prévention ou le traitement de maladie musculaire, contenant comme principe actif decanal ou un sel pharmaceutiquement acceptable de celui-ci Download PDF

Info

Publication number
WO2018070707A1
WO2018070707A1 PCT/KR2017/010751 KR2017010751W WO2018070707A1 WO 2018070707 A1 WO2018070707 A1 WO 2018070707A1 KR 2017010751 W KR2017010751 W KR 2017010751W WO 2018070707 A1 WO2018070707 A1 WO 2018070707A1
Authority
WO
WIPO (PCT)
Prior art keywords
muscle
decanal
composition
preventing
formula
Prior art date
Application number
PCT/KR2017/010751
Other languages
English (en)
Korean (ko)
Inventor
박태선
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Publication of WO2018070707A1 publication Critical patent/WO2018070707A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles

Definitions

  • the present invention relates to a composition for preventing or treating muscle diseases comprising decanal or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the elderly population accounted for 7.2% of the total population in 2000 and entered an aging society.
  • the aged population is expected to enter an aging society (more than 20%).
  • Muscle mass in humans decreases with age (10-15% at 50-70 years, and more than 30% at 70-80 years), thereby weakening muscle strength and muscle function, which is called sarcopenia. do.
  • Geriatric muscular dystrophy is a major cause of limiting the independent living of the elderly by inducing activity disorder and gait disorder.
  • myopathy decreases basal metabolic rate, increases insulin resistance, promotes type 2 diabetes, and increases the risk of hypertension and cardiovascular disease by 3-5 times.
  • drug repositioning technology is being developed to apply myostatin inhibitor or other FDA-approved drugs to myopathy.
  • muscle is divided into skeletal muscle, cardiac muscle, and smooth muscle, and skeletal muscle is the most abundant tissue in the human body, and occupies 40-45% of body weight.
  • Skeletal muscles attach to bones through the tendons, creating bone movement or force.
  • One muscle is made up of numerous myofibers, which in turn are made up of numerous myofibers composed of actin and myosin. When actin and myosin overlap each other, they shorten or lengthen the muscles, causing the entire muscle to contract and relax.
  • An increase in myofibril size means an increase in myofiber thickness, resulting in an increase in muscle.
  • Type IIA and Type B The types of muscle fibers that make up muscle are classified into Type, Type IIA and Type B mainly by the metabolic process and contraction rate that produce ATP.
  • 'Type muscle fiber' has a slow contraction rate and contains a large number of myoglobin and mitochondria, which is suitable for continuous and low-intensity aerobic activity.
  • Type muscle fibers have a red color and are also referred to as red muscles, and soleus is typical.
  • 'Type B muscle fiber' is very short due to its fast shrinkage rate, but is used for high intensity anaerobic exercise, and has a low content of myoglobin, resulting in white color.
  • Type A muscle fibers follow the intermediate characteristics of the two muscle fibers mentioned above. As you get older, the type of muscle and type II muscle fibers change, as well as all types of muscle fibers.
  • Skeletal muscles have the characteristics of being regenerated and maintained according to the environment, but these characteristics are lost with age, and consequently, as aging progresses, muscle mass is reduced and muscle strength is also lost.
  • Signaling systems involved in the growth and regeneration of muscle include signaling mediated by insulin like growth factor 1 (IGF-1) / AKT to regulate protein synthesis.
  • IGF-1 receptor IGF-1R
  • the activation of IGF-1 receptor (IGF-1R) in the muscle cell membrane increases AKT phosphorylation through IRS1 and PI3K phosphorylation, and the latter activates mTORC phosphorylation.
  • Activation of mTORC increases the phosphorylation of ribosomal protein S6 kinase beta-1 (P70S6K1), increases mRNA translation, increases eukaryotic translation initiation factor 4 G (eIF4G) activity, and eukaryotic translation initiation factor 4E binding protein Phosphorylate 1 (4E-BP1) protein.
  • eIF4G and 4E-BP1 are involved in the formation of the eIF4F complex, that is, eIF4G binds to eIF4A and eIF4E to form an eIF4F complex, while phosphorylation of 4E-BP1 inhibits its binding to eIF4E, leading to an increase in free eIF4E. .
  • the latter combines with other translation initiation factors (eIF4G and eIF4A) to form an eIF4F complex, which in turn promotes translation initiation by stabilizing ribosomal structures, ultimately increasing protein synthesis.
  • AKT phosphorylation stimulates muscle fiber growth by increasing eIF2B expression through glycogen synthase kinase 3 (GSK3) and also inhibits muscle loss by inhibiting the expression of forkhead box O (FOXO), a protein-related transcription factor.
  • Muscle loss is regulated by signaling mediated by receptors of the TGF- ⁇ family, including myostatin, transforming growth factor beta (TGF- ⁇ ), and activin. Binding of the ligand to the TGF- ⁇ type II receptor phosphorylates the type I receptor, the latter phosphorylates the smad 2/3 complex and eventually activates FOXO.
  • Muscle Atrophy F-Box Muscle Atrophy F-Box (MaFbx) / atrogin-1, which attach ubiquitin to the lysine site of the target protein. Promote proteolysis, eventually leading to muscle loss.
  • the present inventors have attempted to develop a food material that is effective in improving muscles and improving muscle loss by inhibiting the degradation of muscle proteins and promoting synthesis in natural products with few side effects.
  • the present inventors have tried to find a naturally derived compound that can prevent or treat muscle diseases without side effects. As a result, the mechanism of muscle enhancement and muscle loss action of decanal was identified.
  • an object of the present invention is to solve the above problems, prevent or treat muscle diseases comprising a decanal compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient It is to provide a pharmaceutical composition.
  • Still another object of the present invention is to provide a health functional food composition for preventing or improving muscle diseases including a decanal compound or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Still another object of the present invention is to provide a pharmaceutical composition for promoting muscle differentiation, muscle regeneration, or muscle strengthening, including a decanal compound or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Still another object of the present invention is to provide a health functional food composition for promoting muscle differentiation, muscle regeneration or muscle enhancement, including a decanal compound or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Still another object of the present invention is to provide a decanal compound or a pharmaceutical composition for improving muscle function, including a pharmaceutically acceptable salt thereof as an active ingredient.
  • Still another object of the present invention is to provide a composition for animal feed for preventing or treating muscle diseases, including a decanal compound or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention is to provide a method for preventing or treating muscle diseases, including administering a composition comprising decanal or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention is to provide a use of a composition comprising decanal or a pharmaceutically acceptable salt thereof as an active ingredient for the preparation of a preventive or therapeutic agent for muscle diseases.
  • the present invention provides a pharmaceutical composition for preventing or treating muscle diseases comprising a decanal compound represented by the following Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the composition may be to increase the expression of p-4E-BP1 or p-p70S6K1 protein.
  • the composition may be to reduce the expression of MuRF1 (Muscle Ring-Finger Protein) or MaFbx (Muscle atrophy F-box).
  • MuRF1 Muscle Ring-Finger Protein
  • MaFbx Muscle atrophy F-box
  • the compound may be included in the composition at a concentration of 0.1 to 1000 ⁇ M.
  • the muscle disease may be a muscle disease due to muscle function degradation, muscle reduction, muscle wasting or muscle degeneration.
  • the muscle disease is atony, muscular atrophy, muscular dystrophy, ataxia, cachexia, rigid spinesyndrome, At least one selected from the group consisting of amyotrophic lateral sclerosis, rigid spinse syndrome, Charcot-Marie-Tooth disease and sarcopenia It may be.
  • the present invention provides a decanal compound or a health functional food composition for preventing or improving muscle diseases, including a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention provides a pharmaceutical composition for promoting muscle differentiation, muscle regeneration or muscle enhancement, including a decanal compound or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention also provides a health functional food composition for promoting muscle differentiation, muscle regeneration, or muscle strengthening, including a decanal compound or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention also provides a decanal compound (Decanal) or a pharmaceutically acceptable salt thereof as an active ingredient provides a cosmetic composition for improving muscle function.
  • a decanal compound (Decanal) or a pharmaceutically acceptable salt thereof as an active ingredient provides a cosmetic composition for improving muscle function.
  • the present invention provides a composition for animal feed for the prevention or treatment of muscle diseases comprising a decanal compound (Decanal) or a pharmaceutically acceptable salt thereof as an active ingredient.
  • a decanal compound (Decanal) or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the livestock may be one livestock selected from the group consisting of cattle, pigs, chickens, ducks, goats, sheep and horses.
  • the present invention relates to a composition for preventing or treating muscle diseases, or improving muscle function, comprising decanal or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the decanal is used to synthesize muscle protein in muscle cells and It is possible to increase the expression of proteins associated with increased muscle mass, and the expression of enzymes involved in muscle protein degradation can be suppressed from the mRNA level, so muscle differentiation, muscle regeneration, Increasing muscle mass can increase muscle strength and inhibit muscle loss. In addition, high fat diets may improve muscle loss and muscle weakness associated with ingestion.
  • composition of the present invention can be used for preventing or treating muscle diseases, muscle differentiation, muscle regeneration and muscle mass increase or muscle function improvement.
  • FIG. 1 shows the change in the thickness of myotubes in mouse myoblasts.
  • FIG. 1A is a microscopic image of giemsa-wright stained root canal cells
  • FIG. 1B is a result of measuring the diameter of the root canal cells, and each value is the mean ⁇ standard error of three crystals in three independent wells. P ⁇ 0.05 indicates statistical significance
  • Figure 2 shows the expression changes of molecules related to protein degradation and synthesis in mouse myoblasts treated with decanal.
  • 2A shows the protein levels of p-4E-BP1, Total 4E-BP1, p-p70S6K1, and Total p70S6K1, and
  • FIG. 2B shows the gene expression levels of MaFbx and MuRF1.
  • Each value is the mean ⁇ standard error of three determinations in three independent wells. P ⁇ 0.05 indicates statistical significance.
  • Figure 3 is a graph showing the results of the increase in the muscle extremities muscle intake by decanal.
  • Figure 4 is a graph showing the change in muscle fiber diameter of mouse muscle tissue by decanal intake.
  • 4a shows rectus femoris, 4b soleus, and 4c gastrocnemius muscle tissues.
  • Deccanal according to the present invention can increase the expression of proteins related to muscle protein synthesis and muscle mass increase in muscle cells, can exhibit an effect of increasing muscle mass in muscle diseases caused by muscle function degradation, muscle wasting or muscle degeneration It is effective as an active ingredient of a composition for preventing or treating diseases.
  • the present invention provides a pharmaceutical composition for preventing or treating muscle diseases comprising a decanal compound represented by Formula 1 below or a pharmaceutically acceptable salt thereof as an active ingredient.
  • decanal of the present invention is an aldehyde-based compound, which may be represented as chemical identification number (CAS No.) 112-31-2, aldehyde C-10, caprinaldehyde, decyl aldehyde, Also known as tinnitus such as decanaldehyde.
  • Deccanal is widely used as an anti-drug agent and as a medicine.
  • the biological activity of decanal reported so far is that decanal is treated in embryos cells of sea urchins and copepods (aquatic animals such as black fleas), causing apoptosis. By inducing reproductive failure (Romano et al.
  • decanal increases the thickness of myotubes, increases the expression of proteins associated with muscle protein synthesis and muscle mass, and reduces the expression of genes that promote the degradation of muscle proteins. It was confirmed that there is a prophylactic or therapeutic effect.
  • composition of the present invention may be characterized by increasing the expression of p-4E-BP1 or p-p70S6K1 protein.
  • composition of the present invention may be characterized by reducing the expression of the MuRF1 (Muscle Ring-Finger Protein) or MaFbx (Muscle atrophy F-box).
  • MuRF1 Muscle Ring-Finger Protein
  • MaFbx Muscle atrophy F-box
  • representative molecules related to protein synthesis include p70S6K1, 4E-BP1, and eIF members, and these three molecules are regulated by higher mTORCs.
  • Activation of mTORc phosphorylates p70S6K1 and activated p70S6K1 phosphorylates 40S ribosomal protein S6 to increase mRNA translation.
  • Activation of mTORC also increases the activity of eIF4G and simultaneously phosphorylates 4E-BP1, both molecules involved in forming the eIF4F complex.
  • eIF4G binds to eIF4A and eIF4E to form an eIF4F complex, while when 4E-BP1 is phosphorylated, its binding ability with eIF4E is inhibited to increase the free eIF4E.
  • the latter combines with other translation initiation factors (eIF4G and eIF4A) to form an eIF4F complex, which in turn promotes translation initiation by stabilizing ribosomal structures, ultimately increasing protein synthesis.
  • MAFbx / Atrogin-1 and MuRF1 are muscle-specific ubiquitin-ligases, which are representative proteins that attach ubiquitin to the lysine site of the target protein to promote protein degradation and ultimately muscle loss.
  • the composition of the present invention was confirmed to change the expression of molecules related to protein synthesis and degradation. Specifically, it was confirmed that the expression of p-4E-BP1 and p-p70S6K1 proteins involved in protein synthesis decreased by dexamethasone treatment in mouse myoblasts treated with decanal was significantly increased. On the other hand, it was confirmed that the expression of mRTA of MaFbx and MuRF1 significantly reduced muscle induction by promoting muscle protein degradation. Through this, the composition of the present invention was confirmed that by increasing the p-4E-BP1 and p-p70S6K1 protein phosphorylation, by inhibiting MuRF1 and MaFbx gene expression can reduce muscle loss and increase the amount of muscle.
  • the pharmaceutical composition for preventing or treating muscle diseases does not specifically limit the content as long as it contains decanal or a pharmaceutically acceptable salt thereof, and preferably may be included in a concentration of 0.1 to 1000 ⁇ M, more Preferably it may comprise a concentration of 0.1 to 500 ⁇ M, more preferably may comprise a concentration of 1 to 100 ⁇ M.
  • the myofiocytes treated with decanal 100 ⁇ M increased 74% in thickness of myotubes reduced by dexamethoasone treatment.
  • the muscle disease of the present invention is preferably a disease reported in the art as a muscle disease caused by muscle function decline, muscle loss, muscle wasting or muscle degeneration, and specifically, atony, muscular atrophy , Muscular dystrophy, muscular dystrophy, cachexia, rigid spinesyndrome, amyotrophic lateral sclerosis, rigid spinse syndrome, Sharco-Marie-Tus disease ( Charcot-Marie-Tooth disease) and sarcopenia is more preferably any one or more selected from the group consisting of, but is not limited thereto.
  • the present invention provides a pharmaceutical composition for promoting muscle differentiation, muscle regeneration or muscle strengthening comprising a decanal compound represented by the following Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. Details of the decanal are as described above.
  • muscle wasting or degeneration is caused by a total factor, acquired factors, aging, etc., muscle wasting is characterized by a gradual loss of muscle mass, muscle weakness, especially skeletal muscle or veterinary muscle and heart muscle.
  • muscle refers to tendons, muscles, and tendons collectively, muscle function or muscle function refers to the ability to exert a force by the contraction of the muscle, the muscle to the maximum contraction force to overcome the resistance Muscle strength that can be exerted; Muscle endurance, the ability to indicate how long or how many times a muscle can repeat contraction and relaxation at a given weight; And quickness, which is the ability to exert a strong force in a short time.
  • the muscle function is dominated by the liver and is proportional to muscle mass.
  • the term "improving muscle function" of the present invention means improving muscle function in a more positive direction.
  • composition for preventing and treating muscle diseases or improving muscle function of the present invention may contain decanal alone or one or more active ingredients exhibiting similar functions with decanal. Inclusion of additional components may further enhance the muscle function improving effect of the composition of the present invention. When the ingredient is added, skin safety, ease of formulation, and stability of the active ingredients may be considered.
  • the pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable salt of decanal.
  • pharmaceutically acceptable refers to a physiologically acceptable and normally does not cause an allergic or similar reaction when administered to a human, wherein the salt is a pharmaceutically acceptable free acid. Acid addition salts formed by acid) are preferred.
  • the pharmaceutically acceptable salt of the decanal may be an acid addition salt formed using an organic acid or an inorganic acid, and the organic acid may be, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, malic acid, Maleic acid, malonic acid, fumaric acid, succinic acid, succinic acid monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, dichloroacetic acid, aminooxyacetic acid, benzenesulfonic acid , p-toluenesulfonic acid or methanesulfonic acid.
  • the organic acid may be, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluor
  • Inorganic acids include, for example, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid or boric acid.
  • the acid addition salt may preferably be in the form of hydrochloride or acetate, more preferably in the form of hydrochloride.
  • the above-mentioned acid addition salts may be prepared by either a) mixing the decanal and acid directly, b) dissolving and mixing it in a solvent or hydrous solvent, or c) placing the decanal in an acid in a solvent or submerged solvent and mixing them. It is prepared by a general salt preparation method.
  • salts that can be additionally salted are gabar salt, gabapentin salt, pregabalin salt, nicotinate, adipate salt, hemimalonate, cysteine salt, acetylcysteine salt, methionine salt, arginine salt, lysine salt, ornithine salt Aspartate.
  • composition for preventing and treating muscle diseases of the present invention may further include a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers may further include, for example, carriers for oral administration or carriers for parenteral administration.
  • Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid and the like.
  • Carriers for parenteral administration may also include water, suitable oils, saline, aqueous glucose, glycols, and the like.
  • stabilizers and preservatives may be further included. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid.
  • Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol.
  • Other pharmaceutically acceptable carriers may be referred to those described in the following documents (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).
  • composition of the present invention can be administered to any mammal, including humans.
  • parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal , Intranasal, intestinal, topical, sublingual or rectal administration.
  • the pharmaceutical composition of the invention may be formulated into a formulation for oral administration or parenteral administration according to the route of administration as described above.
  • buffers e.g. saline or PBS
  • antioxidants e.g. bacteriostatic agents
  • chelating agents e.g. EDTA or glutathione
  • fillers e.g. extenders, binders, adjuvants (e.g. aluminum hydroxide) Side)
  • suspending agents e.g. aluminum hydroxide
  • Solid form preparations for oral administration include tablets, pills, powders, granules, solutions, gels, syrups, slurries, suspensions or capsules, and the like, and the solid form may include at least one excipient in the pharmaceutical composition of the present invention, for example , Starch (including corn starch, wheat starch, rice starch, potato starch, etc.), calcium carbonate, sucrose, lactose, dextrose, sorbitol, mannitol, xylitol, erythritol maltitol, cellulose , Methyl cellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose or gelatin may be prepared by mixing.
  • tablets or sugar tablets can be obtained by combining the active ingredient with a solid excipient and then grinding it, adding suitable auxiliaries and then processing the granule mixture.
  • Liquid preparations for oral use include suspensions, solutions, emulsions, or syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, or preservatives, in addition to water or liquid paraffin, which are commonly used simple diluents. .
  • crosslinked polyvinylpyrrolidone, agar, alginic acid or sodium alginate may be added as a disintegrant, and may further include an anticoagulant, a lubricant, a humectant, a perfume, an emulsifier, a preservative, and the like.
  • compositions of the present invention may be formulated according to methods known in the art in the form of injections, transdermal and nasal inhalants with suitable parenteral carriers.
  • suitable parenteral carriers include, but are not limited to, solvents or dispersion media comprising water, ethanol, polyols (e.g., glycerol, propylene glycol and liquid polyethylene glycols, etc.), mixtures thereof and / or vegetable oils Can be.
  • suitable carriers include Hanks solution, Ringer's solution, phosphate buffered saline (PBS) containing triethanol amine or sterile water for injection, 10% ethanol, 40% propylene glycol and 5% dextrose Etc. can be used.
  • PBS phosphate buffered saline
  • various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like may be further included.
  • the injection may in most cases further comprise an isotonic agent such as sugar or sodium chloride.
  • transdermal administration refers to the topical administration of the pharmaceutical composition to the skin to deliver an effective amount of the active ingredient contained in the pharmaceutical composition into the skin.
  • the compounds used according to the invention may be pressurized packs or by means of suitable propellants, for example dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. It can be delivered conveniently from the nebulizer in the form of an aerosol spray. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount.
  • gelatin capsules and cartridges for use in an inhaler or insufflator can be formulated to contain a mixture of the compound and a suitable powder base such as lactose or starch. Formulations for parenteral administration are described in Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, a prescription generally known in all pharmaceutical chemistries.
  • the pharmaceutical composition for preventing and treating muscle diseases of the present invention can provide a desirable muscle disease prevention and treatment effect when it contains an effective amount of decanal.
  • the "effective amount” refers to an amount that exhibits a higher response than the negative control, and preferably an amount sufficient to improve muscle function.
  • Deccanal may be included in the pharmaceutical composition of the present invention from 0.01 to 99.99%, the balance may be occupied by a pharmaceutically acceptable carrier.
  • the effective amount of decanal included in the pharmaceutical composition of the present invention will vary depending on the form in which the composition is commercialized and the like.
  • the total effective amount of the pharmaceutical composition of the present invention may be administered to a patient in a single dose, and may be administered by a fractionated treatment protocol that is administered in multiple doses for a long time. It is important to administer all of the above factors in such a way that the maximum effect can be obtained in a minimum amount without side effects, which can be easily determined by those skilled in the art.
  • the pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the extent of the disease.
  • Parenteral administration is preferably to be administered in an amount of preferably 0.01 to 50 mg, more preferably 0.1 to 30 mg per kg of body weight per day based on the decanal, and oral administration per day based on decanal It can be administered in one to several times to be administered in an amount of preferably 0.01 to 100 mg, more preferably 0.01 to 10 mg per kg body weight.
  • the dose of decanal is determined in consideration of various factors such as the age, weight, health condition, sex, severity of the disease, diet and excretion rate, as well as the route and frequency of treatment of the pharmaceutical composition.
  • the pharmaceutical composition according to the present invention is not particularly limited to its formulation, route of administration and method of administration as long as the effect of the present invention is shown.
  • the pharmaceutical composition for preventing or treating muscle diseases of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy or biological response modifiers.
  • the pharmaceutical composition for preventing or treating muscle diseases of the present invention may also be provided in the formulation of an external preparation containing decanal as an active ingredient.
  • the pharmaceutical composition for preventing or treating muscle diseases of the present invention is used as an external preparation for skin, it is additionally used as a fatty substance, an organic solvent, a dissolving agent, a thickening agent and a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, and a foaming agent.
  • Fragrance surfactant, water, ionic emulsifier, nonionic emulsifier, filler, metal ion sequestrant, chelating agent, preservative, vitamin, blocking agent, wetting agent, essential oil, dye, pigment, hydrophilic active agent, lipophilic active agent Or any other ingredient commonly used in external preparations for skin, such as lipid vesicles.
  • the ingredients may also be introduced in amounts generally used in the field of dermatology.
  • the pharmaceutical composition for preventing or treating muscle diseases of the present invention may be a formulation such as, but not limited to, ointment, patch, gel, cream or spray.
  • the present invention provides a decanal compound represented by the following formula (Decanal) compound or a pharmaceutically acceptable salt thereof as an active ingredient provides a health functional food composition for preventing or improving muscle diseases. Details of the decanal are as described above.
  • the present invention provides a health functional food composition for promoting muscle differentiation, muscle regeneration or muscle strengthening comprising a decanal compound represented by Formula 1 below or a pharmaceutically acceptable salt thereof as an active ingredient. Details of the decanal are as described above.
  • the decanal of the present invention can increase the extremity muscle strength of the mouse by strengthening the muscle, and can improve the muscle loss and muscle weakness according to the high fat diet.
  • the food composition of the present invention includes all forms such as functional food, nutritional supplement, health food, food additives and feed, and includes animals such as humans or livestock. It is for eating. Food compositions of this type can be prepared in various forms according to conventional methods known in the art.
  • the food composition according to the present invention can be prepared in various forms according to conventional methods known in the art.
  • General foods include, but are not limited to, beverages (including alcoholic beverages), fruits and processed foods (e.g. canned fruit, canned foods, jams, marmalade, etc.), fish, meat and processed foods (e.g. hams, sausages) Cornbread, etc.), breads and noodles (e.g. udon, soba noodles, ramen, spagate, macaroni, etc.), fruit juices, various drinks, cookies, malts, dairy products (e.g.
  • butter, cheese edible vegetable oils
  • margarine It can be prepared by adding the decanal of the present invention to vegetable protein, retort food, frozen food, various seasonings (eg, miso, soy sauce, sauce, etc.).
  • seasonings eg, miso, soy sauce, sauce, etc.
  • a nutritional supplement is not limited to this can be prepared by adding the decanal of the present invention to capsules, tablets, pills, and the like.
  • a health functional food but not limited to, for example, by making the decanal itself of the present invention in the form of tea, juice and drinks to be liquefied, granulated, encapsulated and powdered to drink (healthy drink) It can be ingested.
  • the decanal of the present invention in the form of a food additive, it can be prepared in powder or concentrate form. In addition, it can be prepared in the form of a composition by mixing with the decanal of the present invention and known active ingredients known to be effective in preventing muscle diseases and improving muscle function.
  • the health beverage composition may contain various flavors or natural carbohydrates as additional components, as in general beverages.
  • natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin, cyclodextrin; Sugar alcohols such as xylitol, sorbitol, and erythritol.
  • Sweeteners include natural sweeteners such as taumartin, stevia extract; Synthetic sweeteners such as saccharin and aspartame;
  • the proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.
  • the decanal of the present invention may be contained as an active ingredient of the food composition for preventing muscle diseases and improving muscle function, the amount is not particularly limited to an amount effective to achieve the action for preventing muscle diseases and improving muscle function. It is preferably from 0.01 to 100% by weight relative to the total weight of the total composition.
  • the food composition of the present invention may be prepared by mixing with decanal together with other active ingredients known to be effective in the composition for preventing muscle diseases and improving muscle function.
  • the health food of the present invention is various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, Glycerin, alcohol or carbonation agent, and the like.
  • the health food of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage, or vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
  • the present invention provides a cosmetic composition for improving muscle function comprising a decanal compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient. Details of the decanal are as described above.
  • the cosmetic composition is not particularly limited, but may be used externally or ingested orally.
  • the cosmetic composition of the present invention contains a decanal as an active ingredient and, together with a dermatologically acceptable excipient, a basic cosmetic composition (cleanser such as cosmetic water, cream, essence, cleansing foam and cleansing water, pack, body oil), color cosmetic composition (Foundation, lipstick, mascara, makeup base), hair product composition (shampoo, rinse, hair conditioner, hair gel) and soap and the like.
  • a basic cosmetic composition cleaning such as cosmetic water, cream, essence, cleansing foam and cleansing water, pack, body oil
  • color cosmetic composition Fraundation, lipstick, mascara, makeup base
  • hair product composition shampoo, rinse, hair conditioner, hair gel
  • the excipients include, but are not limited to, emollients, skin penetration enhancers, colorants, fragrances, emulsifiers, thickeners and solvents.
  • fragrances, pigments, fungicides, antioxidants, preservatives and moisturizing agents may be further included, and may include thickeners, inorganic salts, synthetic polymer materials and the like for the purpose of improving the properties.
  • the decanal may be easily added to the face wash and the soap base.
  • it may be prepared by adding decanal or a salt thereof to a cream base of a general oil-in-water type (O / W).
  • synthetic or natural materials such as proteins, minerals, vitamins, etc., for the purpose of improving physical properties, such as flavors, chelating agents, pigments, antioxidants, and preservatives, may be added.
  • the content of decanal contained in the cosmetic composition of the present invention is not limited thereto, but is preferably 0.001 to 10% by weight, more preferably 0.01 to 5% by weight based on the total weight of the composition. If the content is less than 0.001% by weight, the desired anti-aging or anti-wrinkle effect may not be expected, and when the content is more than 10% by weight, there may be difficulty in preparing a safety or formulation.
  • the present invention provides a composition for animal feed for preventing or treating muscle diseases, comprising a decanal compound represented by Formula 1 below or a pharmaceutically acceptable salt thereof as an active ingredient. Details of the decanal are as described above.
  • the feed composition may include a feed additive.
  • the feed additive of the present invention corresponds to a feed supplement in the Feed Control Act.
  • feed may refer to any natural or artificial diet, one meal, or the like, or a component of the one meal, for the animal to eat, ingest, and digest.
  • the kind of the feed is not particularly limited, and may be used a feed commonly used in the art.
  • Non-limiting examples of the feed may include plant feeds such as cereals, fruits, food processing by-products, algae, fibres, pharmaceutical by-products, oils, starches, gourds or grain by-products; And animal feeds such as proteins, minerals, fats and oils, minerals, fats and oils, single cell proteins, zooplankton or foods. These may be used alone or in combination of two or more thereof.
  • the feed additive may additionally contain a carrier that is acceptable to the unit animal.
  • the feed additive may be added as it is, or a known carrier, stabilizer, or the like. If necessary, various nutrients such as vitamins, amino acids, minerals, antioxidants, and other additives may be added. Powders, granules, pellets, suspensions and the like may be in a suitable state.
  • the unit animal may be supplied alone or mixed with feed.
  • Mouse myoblast cell lines (C2C12 cells) were purchased from ATCC (Manassas, VA, USA) and used. The purchased cells were incubated in 37, 5% CO 2 incubator using 10% feta bovine serum (FBS) media and used in the experiment. When the cells became 80% confluent, they were differentiated into myotubes using 2% Horse serum (HS) media. Two days from the 4 th day of differentiation, dexamethasone (50 ⁇ M) and decanal (100 ⁇ M) were treated together.
  • FBS feta bovine serum
  • the cells were washed twice with Phosphate buffered saline (PBS) and fixed for 10 minutes with 100% methanol. When the fixation was completed, the resultant was dried for 10 minutes at room temperature, and then stained for 30 minutes by dropping Giemsa-wright staining solution (Seoul, Asan Pharmaceutical) that specifically stained myotubes.
  • PBS Phosphate buffered saline
  • the thickness of myotube was significantly reduced in control cells (Dexa) compared to normal cells (Basal), and decanal treatment was visually confirmed to increase the thickness of myotube reduced by dexamethasone again (FIG. 1A). Deccanal treatment also increased 74% of myotube thickness, which was significantly reduced by dexamethasone, even after quantification using image J software (FIG. 1B). Therefore, decanal increases the thickness of myotube in mouse myoblasts, inhibits muscle loss and promotes muscle growth.
  • RNA pellet was dissolved using nuclease free water.
  • UV / VIS spectrophotometer Beckman coulter, DU730 was measured the concentration of RNA samples extracted at 260 nm and 280 nm wavelength, and the integrity of the RNA samples were confirmed by agarose gel electrophoresis.
  • RNA samples extracted from mouse myoblasts were synthesized by reverse transcription using oligo dT primer and superscript reverse transcriptase (GIBCO BRL, Gaithersburg, MD, USA). PCR was performed using 5 'and 3' flanking sequences of the gene cDNA to be amplified as a template and cDNA obtained through reverse transcription. The primer sequences used are shown in [Table 1]. 1 ⁇ l of the amplified PCR product was electrophoresed on 1% agarose gel to confirm DNA bands.
  • the primary antibody is Foxo, phospho-foxo (p-foxo), S6K1, phopho-S6K1 (p-S6K1), 4EB-P1, phospho-4EBP-1 and GAPDH (Cell Signaling Technology, Beverly, MA, USA ) was used.
  • the proteins were visualized on an X-ray film using an ECL Western blot detection kit (RPN2106, Amersham, Arlington Heights, IL, USA). Bands visualized on the X-ray film were scanned and quantified using Quantity One analysis software (Bio-Rad).
  • mice Twenty five-week-old male C57BL / 6N mice (mating, Korea) were adapted to a laboratory environment for one week as a commercial rodant chow, and then three groups (Chow, HFD, and Decanal) according to the ingot method. ) Were randomly placed and bred for 10 weeks.
  • the obesity induction diet used in this study was a high fat diet (HFD: 40% fat calorie, 17 g lard + 3% corn oil / 100 g diet) and was supplemented with decanal supplement (decanal-supplemented high).
  • fat diet, Decanal was prepared to have the same composition as HFD but contained 0.2% decanal.
  • the experimental dietary table is shown in Table 2 below.
  • HFD High fat control diet
  • Decanal Supplementary diet Decanal
  • Casein 200 200 DL-Methionine 3 3
  • Corn starch 111 107 Sucrose 370 370 cellulose 50 50 Corn oil 30 30
  • Laad 170 170 Vitamin complex 12 12
  • Mineral complex 42 Choline Bitartrate 2
  • cholesterol 10
  • tert-butyhydroquinone 0.04 0.04 Decanal - 2 Total (g) 1,000 1,000 Fat (% calories) 39.0 39.0 Total calories, kJ / kg diet 19,315 19,315
  • Muscle tissues of the mice were extracted and fixed in 10% formalin, and then stained with hematoxylin and eosin (H & E) and observed using an optical microscope (IX71, Olympus, JPN). Photos were taken using a digital camera (DP71, Olympus, JPN) and muscle fiber diameters were measured using an image Jay program.
  • the muscle fiber diameter of the Rectus femoris (FIG. 4A), soleus (FIG. 4B), gastrocnemius (FIG. 4C) muscle significantly reduced the intake of Chow than the intake of Chow, decane
  • the high fat diet was significantly increased compared to the control group.
  • decanal can be seen that the effect of improving the muscle loss and muscle weakness of mice fed a high-fat diet is very excellent.
  • the above ingredients were mixed and filled in an airtight cloth to prepare a powder.
  • tablets were prepared by tableting according to a conventional method for producing tablets.
  • the above components are dissolved in purified water according to a conventional preparation method, dissolved in purified water, and then lemon juice is added in an appropriate amount. After adjusting to 100 mL in total, sterilized and filled in a brown bottle to prepare a liquid formulation.
  • Vitamin B 1 0.13 mg
  • Vitamin B 2 0.15 mg
  • Vitamin B 6 0.5 mg
  • composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method.
  • the granules may be prepared and used for preparing a health food composition according to a conventional method.
  • composition ratio is mixed with a component suitable for a favorite beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
  • the compounding ratio is mixed with a component suitable for nutritional longevity in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
  • the compounding ratio is mixed and formulated in a preferred embodiment with a component suitable for a relatively softening longevity
  • the compounding ratio may be arbitrarily modified, and can be prepared according to the manufacturing method in the general cosmetic field.
  • the compounding ratio is mixed with a component suitable for nourishing cream in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
  • the compounding ratio is mixed with a component suitable for a massage cream in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a manufacturing method in the general cosmetic field.
  • the compounding ratio is mixed with a component suitable for a pack in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a manufacturing method in the general cosmetic field.
  • the compounding ratio is mixed with a component suitable for a gel in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
  • the blending ratio is a relatively suitable composition for the cosmetic composition in a preferred embodiment, but can be applied to cosmetics of various uses, including other color cosmetics, according to the efficacy that can be applied to a thin coating on the human body, that is, It can be used for manufacturing as an ointment, and the compounding ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Health & Medical Sciences (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition pour la prévention ou le traitement d'une maladie musculaire ou l'amélioration de la fonction musculaire et comprenant Décanal ou un sel pharmaceutiquement acceptable de celui-ci comme principe actif et, plus spécifiquement, une composition pharmaceutique pour prévenir ou traiter une maladie musculaire, une composition à base d'aliments fonctionnels diététiques pour prévenir ou améliorer une maladie musculaire, une composition pharmaceutique pour favoriser la différenciation musculaire ou pour régénérer ou renforcer un muscle, une composition à base d'aliments fonctionnels diététiques pour favoriser la différenciation musculaire ou pour régénérer ou renforcer un muscle, une composition cosmétique pour améliorer la fonction musculaire, et une composition à base d'aliments pour le bétail pour prévenir ou traiter une maladie musculaire, qui comprennent Décanal ou un sel pharmaceutiquement acceptable de celui-ci comme principe actif.
PCT/KR2017/010751 2016-10-13 2017-09-27 Composition pour la prévention ou le traitement de maladie musculaire, contenant comme principe actif decanal ou un sel pharmaceutiquement acceptable de celui-ci WO2018070707A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160132845A KR101842948B1 (ko) 2016-10-13 2016-10-13 데칸알 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물
KR10-2016-0132845 2016-10-13

Publications (1)

Publication Number Publication Date
WO2018070707A1 true WO2018070707A1 (fr) 2018-04-19

Family

ID=61901652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/010751 WO2018070707A1 (fr) 2016-10-13 2017-09-27 Composition pour la prévention ou le traitement de maladie musculaire, contenant comme principe actif decanal ou un sel pharmaceutiquement acceptable de celui-ci

Country Status (2)

Country Link
KR (1) KR101842948B1 (fr)
WO (1) WO2018070707A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101997334B1 (ko) * 2017-07-18 2019-07-08 연세대학교 산학협력단 퓨라네올을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물
KR101923153B1 (ko) * 2018-08-02 2018-11-28 충남대학교산학협력단 갈산을 유효성분으로 포함하는 근 분화 촉진용 조성물
KR102130240B1 (ko) * 2019-01-07 2020-07-03 연세대학교 산학협력단 탄소수 14 내지 17의 직쇄 알칸을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물
WO2021167123A1 (fr) * 2020-02-18 2021-08-26 연세대학교 산학협력단 Composition comprenant un alcane à chaîne droite comportant de 14 à 17 atomes de carbone utilisé comme principe actif, pour le renforcement musculaire, l'amélioration musculaire, la différenciation musculaire, la régénération musculaire ou la suppression d'une sarcopénie

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013168021A1 (fr) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions et méthodes pour le traitement des troubles neuromusculaires et des troubles neurodégénératifs
KR20140042759A (ko) * 2012-09-28 2014-04-07 한국생명공학연구원 아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
US20140302023A1 (en) * 2011-11-07 2014-10-09 UNIVERSITé LAVAL Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
KR20150024586A (ko) * 2013-08-27 2015-03-09 (주)네오팜 근육 분화 촉진 및 근육 강화용 조성물 및 외용제
KR20150142536A (ko) * 2014-06-12 2015-12-22 한국생명공학연구원 부틸 피리디늄 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140302023A1 (en) * 2011-11-07 2014-10-09 UNIVERSITé LAVAL Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
WO2013168021A1 (fr) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions et méthodes pour le traitement des troubles neuromusculaires et des troubles neurodégénératifs
KR20140042759A (ko) * 2012-09-28 2014-04-07 한국생명공학연구원 아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
KR20150024586A (ko) * 2013-08-27 2015-03-09 (주)네오팜 근육 분화 촉진 및 근육 강화용 조성물 및 외용제
KR20150142536A (ko) * 2014-06-12 2015-12-22 한국생명공학연구원 부틸 피리디늄 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
KR101842948B1 (ko) 2018-03-28

Similar Documents

Publication Publication Date Title
WO2018070707A1 (fr) Composition pour la prévention ou le traitement de maladie musculaire, contenant comme principe actif decanal ou un sel pharmaceutiquement acceptable de celui-ci
WO2020218720A1 (fr) Composition pour la prévention ou le traitement de troubles musculaires ou l'amélioration de la fonction musculaire, contenant un extrait de leonurus japonicus ou de la léonurine
WO2018070705A1 (fr) Composition pour prévenir ou traiter des maladies musculaires, contenant, en tant que principe actif, de la diosmine ou un sel pharmaceutiquement acceptable de cette dernière
WO2014058160A1 (fr) Composition comprenant de la myricétine en tant que composant actif pour améliorer les performances d'effort ou la récupération de la fatigue
WO2010087577A2 (fr) Utilisation d'extrait de thymus capitatus, d'extrait de satureja hortensis, ou de carvacrol pour traiter des maladies métaboliques
WO2018128479A1 (fr) Composition pour la prévention ou le traitement de maladies musculaires, comprenant comme principe actif de l'acide subérique ou un sel pharmaceutiquement acceptable de celui-ci
WO2018128483A1 (fr) Composition pour la prévention ou le traitement de maladies musculaires, comprenant de l'ocimène, de l'eugénol ou un sel pharmaceutiquement acceptable de ceux-ci en tant que principe actif
WO2018236186A1 (fr) Composition comprenant un dérivé de sesquiterpène en tant que principe actif pour la prévention ou le traitement de maladies musculaires
WO2018004141A1 (fr) Composition ayant pour effet d'améliorer l'hydratation de la peau, d'exfolier la peau, d'améliorer l'élasticité de la peau, d'inhiber l'érythème, d'atténuer les rides cutanées ou d'atténuer le photovieillissement cutané, contenant, en tant qu'ingrédient actif, un ou plusieurs composés choisis dans le groupe constitué du cimène, de l'acide béhénique, du 2-méthoxynaphtalène, du thymol et de leurs sels
WO2020085826A1 (fr) Composition pour soulager une irritation de la peau induite par des facteurs de pollution environnementaux ou pour la protection de la peau, contenant comme principe actif un extrait de noix de muscade ou du macelignane
WO2019017677A9 (fr) Composition comprenant du citral utilisé comme principe actif pour présenter un effet de raffermissement musculaire, de renforcement musculaire, de différenciation musculaire, de régénération musculaire ou de suppression de sarcopénie
WO2018062820A1 (fr) Composition visant à prévenir la chute des cheveux et à en favoriser la pousse, comprenant un phytoœstrogène en tant que principe actif
WO2018186641A1 (fr) Composition pour réduire les rides de la peau, hydrater la peau, améliorer son élasticité, l'exfolier, inhiber l'érythème ou réduire le photovieillissement de la peau, contenant du pipéronal ou l'un de ses sels à titre de principe actif
WO2020032435A1 (fr) Composition de prévention de la perte des cheveux ou de promotion de la restauration capillaire contenant du yarayara en tant qu'ingrédient actif
WO2017142265A1 (fr) Composition contenant de l'acide adipique utilisé comme principe actif pour l'atténuation des rides de la peau et l'amélioration de l'élasticité de la peau
WO2018128482A1 (fr) Composition, comprenant un cymène ou un sel pharmaceutiquement acceptable de celui-ci comme principe actif, pour la prévention ou le traitement de maladie musculaire
WO2019017676A2 (fr) Composition comprenant de l'éthylvanilline en tant que principe actif pour conférer un effet de renforcement musculaire, d'amélioration musculaire, de différenciation musculaire, de régénération musculaire ou de suppression de sarcopénie
WO2016190689A2 (fr) Composition permettant de prévenir, de soulager ou de traiter les maladies musculaires ou d'améliorer la fonction musculaire
WO2015037855A1 (fr) Composition comprenant un extrait d'herbes combinées comprenant de l'acanthopanax koreanum naka et du crinum asiaticum var. japonicum présentant une activité de prévention de la calvitie et une activité de stimulation de la croissance capillaire
WO2019172566A1 (fr) Agent anti-stress, composition d'agent anti-anxiété ou antidépresseur contenant de l'ionone en tant que principe actif
WO2018128478A1 (fr) Composition, comprenant comme principe actif de l'ionone ou un sel pharmaceutiquement acceptable de celle-ci, destinée à la prévention ou au traitement de troubles musculaires
WO2018128481A1 (fr) Composition destinée à la prévention ou au traitement de maladies musculaires, comprenant comme principe actif de l'indole-3-carbinol ou un sel pharmaceutiquement acceptable de celui-ci
WO2018128480A1 (fr) Composition destinée à la prévention ou au traitement de maladies musculaires, comprenant de l'acide géranique ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif
WO2020145619A1 (fr) Composition pour la prévention des allergies, le soulagement de la dermatite atopique ou la régénération de la peau, contenant, en tant que principe actif, un undécane ou un undécanal
WO2019198982A1 (fr) Composition pour prévenir ou améliorer l'atrophie musculaire squelettique contenant de la kukoamine a et de la kukoamine b en tant que principes actifs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17861076

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17861076

Country of ref document: EP

Kind code of ref document: A1